TOI

$3.59

Post-MarketAs of Mar 17, 8:00 PM UTC

The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.59
Potential Upside
5%
Whystock Fair Value$3.77
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Care Facilities

The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$354.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.31

Recent News

Motley Fool
Mar 17, 2026

Oncology Institute (TOI) Earnings Transcript

Daniel Virnich: Thank you, Mark. Good afternoon, everyone, and thank you for joining our fourth quarter and full year 2025 earnings call. Most importantly, the fourth quarter marked an important milestone being our first profitable quarter as a public company from an adjusted EBITDA perspective.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 13, 2026

The Oncology Institute Inc (TOI) Q4 2025 Earnings Call Highlights: Record Revenue and First ...

The Oncology Institute Inc (TOI) reports a milestone quarter with significant revenue growth and strategic expansions, despite upcoming challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 13, 2026

Oncology Institute Q4 Earnings Call Highlights

The Oncology Institute (NASDAQ:TOI) reported fourth-quarter and full-year 2025 results highlighted by what management described as its first profitable quarter as a public company on an adjusted EBITDA basis, alongside continued growth in its capitated and pharmacy dispensing businesses. CEO Daniel

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 26, 2026

Alignment Healthcare (ALHC) Reports Q4 Loss, Beats Revenue Estimates

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of +67.04% and +1.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Jan 9, 2026

Is Oncology Institute (TOI) Quietly Rewiring Its Edge Around AI Talent And Boardroom Financial Discipline?

The Oncology Institute, Inc. recently promoted long-time technology leader Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer, while also adding RadNet CFO Mark Stolper to its Board of Directors. These leadership moves highlight a growing emphasis on AI-enabled technology, data privacy, and talent management, combined with additional healthcare finance expertise at the board level. We’ll now explore how the CIO’s AI-focused mandate and the new board...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.